Clicky

GeneOne Life Science Inc(011000)

Description: GeneOne Life Science, Inc., a biopharmaceutical company, engages in the development and contract manufacturing of gene-based-biomedicines. Its products comprise GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company also develops GLS-3000 and GLS-5310 for the treatment of SARS-CoV-2; GLS-5100 to treat VZV-Shingles; and GLS-5140 for the treatment of SFTS. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C, as well as GLS-6100 that is in pre-clinical stage for hepatitis C. Further, the company, through its subsidiary, VGXI, Inc., engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.


Keywords: Biopharmaceutical Contract Manufacturing Inflammatory Diseases Hepatitis C Treatment Of Hepatitis C Zika

Home Page: www.genels.com

The Pinnacle Gangnam
Seoul, 06060
South Korea
Phone: 82 2 6004 3450


Officers

Name Title
Mr. Young-Keun Park J.D., M.B.A. CEO & Director
Mr. Byung-Mun Cho B.A., M.B.A. Exec. VP & Exec. Director
Je-Kyung Che Exec.
Han-Mo Park Exec.
Ho-Joon Lee Exec.
Won-Young Jeong Exec.
Nak-Young Kim Exec.
Heung-Won Seo Exec.
Chang-Hoon Song Exec.
Yoon-Jin Lee Exec.

Exchange: KO

Country: KR

Currency: Korean Won (₩)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.8369
Price-to-Sales TTM: 14.3
IPO Date:
Fiscal Year End: December
Full Time Employees: 61
Back to stocks